1. Universal vaccine phase 1 results

    Given how frequently SARS-CoV-2 mutates, this is welcome news…. 👍 “”The first pan-coronavirus ("universal") vaccine Phase 1 clinical trial results are encouraging for eliciting broad sarbecovirus, #SARSCoV2 variant immune response.”- r/t E Topol. Link #covid19 #covid #vaccine
  2. GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold

    By Lara Goldstein After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS ) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary inhalable 5-MeO-DMT compound GH001 on clinical hold due to “ins
  3. Filament Health Shares Q1 2023 Financials, Material Uncertainties Upon Securing Additional Financing

    By Lara Goldstein Natural psychedelic drug development company Filament Health (OTCQB: FLHLF ) has released its unaudited consolidated, condensed financial results for Q1 2023 ended June 30. Numbers show: Total cash of $860.324 (CA$1.16 million) as of June 30, 2023, compared to the $